• Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review

• The metabolic nature of inflammatory bowel diseases

• Extra-Colonic Malignancy in Inflammatory Bowel Disease: a Paucity of Recommendations with Weak Evidence

• Diets for inflammatory bowel disease: What do we know so far?

• Histological features of Clostridioides difficile colitis in patients with inflammatory bowel disease

• Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

• Inflammatory bowel disease in underserved populations: lessons for practice

• Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis

• Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD

• MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer

• Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?

• Advances in the Comprehensive Management of Postoperative Crohn's Disease

• Intestinal Inflammation Promotes MDL-1 +Osteoclast Precursor Expansion to Trigger Osteoclastogenesis and Bone Loss

• Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial

• Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

• Current Applications of Telemedicine in Gastroenterology

• Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States

• Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study

• High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease

• The future of telemedicine and wearable technology in IBD

• Precision medicine: how multiomics will shape the future of inflammatory bowel disease?

• Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge

• The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease

• Microenvironmental Factors that Shape Bacterial Metabolites in Inflammatory Bowel Disease

• Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review

• Management of refractory inflammatory bowel disease

• Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

• Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21 st Century: A Systematic Review with Temporal Analyses

• Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis

• Diet as a treatment for inflammatory bowel disease: is it ready for prime time?

• Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview

• A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases

• Risk of Cervical Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Population-Based Studies

• Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review

• Risk of ulcerative colitis and Crohn's disease in smokers lacks causal evidence

• Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study

• The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis

• Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease

• Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study

• Inflammatory bowel disease as a new risk factor for dementia

• Risk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

• Interventions to improve medication adherence in inflammatory bowel disease: A systematic review

• Prevalence and Risk Factors for Fatigue in Adults With Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis

• A Systematic Review of Artificial Intelligence and Machine Learning Applications to Inflammatory Bowel Disease, with Practical Guidelines for Interpretation

• Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease

• Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial

• Anti-TNF induced rashes in inflammatory bowel disease - a systematic review and evidence-based algorithm for management

• Can an online expressive writing program support people with inflammatory bowel disease? A feasibility randomised controlled trial

• A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease

• Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

• Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial

• Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

• MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases

• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

• What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

• Personalised Medicine with IL-23 Blockers: Myth or Reality?

• Blockade of IL-23: What is in the Pipeline?

• Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease

• Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease

• Gastrointestinal Conditions: Inflammatory Bowel Disease

• Depression and Inflammatory Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study

• Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey

• Chronic Granulomatous Disease With Inflammatory Bowel Disease: Clinical Presentation, Treatment, and Outcomes From the USIDNET Registry

• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

• Decision making about anti-TNF therapy: A pilot trial of a shared decision-making intervention

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

• Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease: A Series of N-of-1 Diet Trials

• SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

• Multimodal stress reduction and lifestyle modification program for patients with ulcerative colitis: a qualitative study

• Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy

• Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial

• Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis

• Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

• Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial

• Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study

• Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

• Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

• Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial

• Endoscopic Prediction of Crohn's Disease Postoperative Recurrence

• A Care Coordination Intervention Improves Symptoms But Not Charges in High-Risk Patients With Inflammatory Bowel Disease

• Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease

• Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Stud

• Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial

• Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study

• Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

• Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

• Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

• Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease

• Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease

• Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease

• Surgical closure, mainly with glue injection and anti-tumour necrosis factor a, in fistulizing perianal Crohn's disease: A multicentre randomized controlled trial

• Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease

• Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis

• Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months

• Demographic Factors Associated With Successful Telehealth Visits in Inflammatory Bowel Disease Patients

• High Rates of Mortality in Geriatric Patients Admitted for Inflammatory Bowel Disease Management

• Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry

• Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial

• Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

• Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program

• The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease

• Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease

• National Prevalence of Psychological Distress and Use of Mental Health Care in Inflammatory Bowel Disease

• Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent

• Effect of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study

• Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results

• Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease

• Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis

• Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

• Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin

• Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

• Bilateral pulmonary embolism and pulmonary infarctions in active ulcerative colitis

• COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience

• Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy

• Review article: emerging drug therapies in inflammatory bowel disease

• Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease

• COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Diseases at a Diverse Safety Net Hospital

• Early Pouchitis Is Associated With Crohn's Disease-like Pouch Inflammation in Patients With Ulcerative Colitis

• Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients

• Disrupted Circadian Rest-Activity Cycles in Inflammatory Bowel Disease Are Associated With Aggressive Disease Phenotype, Subclinical Inflammation, and Dysbiosis

• Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare

• Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease

• A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease

• Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images

• The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD

• Development and Validation of the Gastrointestinal Unhelpful Thinking Scale (GUTs): A Brief Self-Report Measure for Clinical and Research Settings

• Relationship Between Endoscopic and Clinical Disease Activity With Fatigue in Inflammatory Bowel Disease

• Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer

• Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study

• An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI

• Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis

• The Relationship Between Opioid Use and Healthcare Utilization in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

• Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System

• The Cumulative Incidence of Pouchitis in Pediatric Patients With Ulcerative Colitis

• Food-Related Quality of Life in Children and Adolescents With Crohn's Disease

• Modelling symptoms to suicide risk in individuals with inflammatory bowel disease

• Lived experience in people with inflammatory bowel disease and comorbid anxiety and depression in the United Kingdom and Australia

• Patients with More Severe IBD Get Clostridioides difficile Rather than Clostridioides difficile Increasing the Severity of IBD

• Patients' perspectives on medication for inflammatory bowel disease: a mixed-method systematic review

• Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease

• Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study

• Prevalence of Gastrointestinal Symptoms and Irritable Bowel Syndrome Among Individuals With Symptomatic Posttraumatic Stress Disorder

• Disease Monitoring in IBD: evolving principles and possibilities

• Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study

• How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease

• Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey

• Prescribing for pregnancy: inflammatory bowel disease

• Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study

• A systematic review of the patient burden of Crohn's disease-related rectovaginal and anovaginal fistulas

• Impact of Obesity on Inflammatory Bowel Disease

• Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID

• Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients

• Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease

• Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration

• 'These Discussions Aren't Happening': Experiences of People Living with Inflammatory Bowel Disease and Talking About Sexual Well-being with Health Care Professionals

• Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis

• Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease

• Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn's Disease Patients

• Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

• Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis

• Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device

• Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis

• Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients

• Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future

• The Burden of Inflammatory Bowel Disease in Europe in 2020

• Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium

• SSAT State-of-the-Art Conference: Advancements in the Microbiome

• Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

• Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease

• Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders

• Coping Behaviors of African Americans With Inflammatory Bowel Disease: A Focused Ethnography

• Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification

• Financial Toxicity in People With Inflammatory Bowel Disease

• Rising Rate of Obesity in Patients Admitted for Crohn's Disease Increases Costs But Not Mortality

• Clinical and Genetic Factors Impact Time to Surgical Recurrence After Ileocolectomy for Crohn's Disease

• Hyperbaric Oxygen Therapy in Chronic Inflammatory Conditions of the Pouch

• Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort

• No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification

• Neutrophil dysfunction triggers inflammatory bowel disease in G6PC3 deficiency

• Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease

• Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium

• Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease

• Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis

• The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies

• Perspectives on an Acceptance and Commitment Therapy (ACT) based program for patients with inflammatory bowel disease and comorbid anxiety and/or depressive symptoms

• Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis

• Serrated Epithelial Change Is Associated With High Rates of Neoplasia in Ulcerative Colitis Patients: A Case-controlled Study and Systematic Review With Meta-analysis

• Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD

• Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

• Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

• Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients

• Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

• Prevalence and Impact of Post-traumatic Stress Disorder in Gastrointestinal Conditions: A Systematic Review

• Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis

• Crohn's disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis

• Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG

• Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium

• Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

• Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders

• Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG

• Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium

• Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

• Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders

• Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice

• Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study

• Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?

• Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts

• National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States

• Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease

• Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy

• The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies

• Patient Strategies for Managing the Vicious Cycle of Fatigue, Pain and Urgency in Inflammatory Bowel Disease: Impact, Planning and Support

• Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease

• Vitamin D Receptor Gene Single Nucleotide Polymorphisms and Association With Vitamin D Levels and Endoscopic Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Study

• Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease

• Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium

• Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic

• Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease

• Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians

• Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location

• Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease

• Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases

• Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada and the United Kingdom

• Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure

• Ocular Manifestations of Inflammatory Bowel Disease

• Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease

• End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease

• Delivery Outcomes of Pregnant Patients With Inflammatory Bowel Diseases Compared With the General Population and With Women With Other Autoimmune Diseases at a Tertiary Care Center

• Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience

• Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease

• Efficacy and safety of adalimumab in pediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study

• Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease

• Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score

• Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021

• Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review

• Surgical management of Crohn's disease: a state of the art review

• Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy

• Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease

• Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How

• SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

• Ileal pouch-anal anastomosis in the elderly: A systematic review and meta-analysis

• Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors

• When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?

• IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore

• Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work

• A Feeling of Otherness: A Qualitative Research Synthesis Exploring the Lived Experiences of Stigma in Individuals with Inflammatory Bowel Disease

• Effects of yoga in inflammatory bowel diseases and on frequent IBD-associated extra-intestinal symptoms like fatigue and depression

• A randomized, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

• A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD

• Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials

• Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease

• Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease

• Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey

• Perioperative safety of tofacitinib in surgical ulcerative colitis patients

• Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach

• Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease

• Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study

• Family planning with inflammatory bowel disease: the challenge of childlessness and parent concerns

• Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

• Patients Undergoing Ileoanal Pouch Surgery Experience a Constellation of Symptoms and Consequences Representing a Unique Syndrome: A Report From the Patient-Reported Outcomes After Pouch Surgery (PROPS) Delphi Consensus Study

• Defining the Economic Burden of Perioperative Venous Thromboembolism in Inflammatory Bowel Disease in the United States

• Effects of yoga in inflammatory bowel diseases and on frequent IBD-associated extraintestinal symptoms like fatigue and depression

• A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

• A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD

• Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials

• Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease

• Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors

• When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?

• IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore

• Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work

• A Feeling of Otherness: A Qualitative Research Synthesis Exploring the Lived Experiences of Stigma in Individuals with Inflammatory Bowel Disease

• Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders

• What Is a Flare? The Manitoba Living With IBD Study

• Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?

• Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

• Shared decision making in pregnancy in inflammatory bowel disease: design of a patient orientated decision aid

• Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders

• What Is a Flare? The Manitoba Living With IBD Study

• Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?

• Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

• Shared decision making in pregnancy in inflammatory bowel disease: design of a patient orientated decision aid

• Revisiting the Association Between Inflammatory Bowel Disease and Parkinson's Disease

• A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease

• The evolution of IBD perceived engagement and care needs across the life-cycle: a scoping review

• Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor a Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience

• Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study

• The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients

• Sustainable generation of patient-led resources in a learning health system

• Health Maintenance Consensus for Adults With Inflammatory Bowel Disease

• Review of a paediatric inflammatory bowel disease service during the pandemic and the impact of the CNS role

• Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease

• Inflammatory Bowel Disease: Its Effects on Physical Activity, Sports Participation, and Athletes

• Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients

• Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations

• Higher Levels of Psychological Burden and Alterations in Personality Functioning in Crohn's Disease and Ulcerative Colitis

• A meta-analysis on sleep quality in inflammatory bowel disease

• Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients

• Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018

• Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

• Disease Activity Indices for Pouchitis: A Systematic Review

• ECCO topical review: Refractory IBD

• Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study

• Comorbidity before and after a diagnosis of inflammatory bowel disease

• Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice

• What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries

• Female reproductive health and inflammatory bowel disease: A practice-based review

• Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-a during pregnancy: A systemic review and meta-analysis

• Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19

• The complexities of approaching nutrition in inflammatory bowel disease: current recommendations and future directions

• High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases

• Physical Activity in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study

• Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

• Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines

• IBD goes home: from telemedicine to self-administered advanced therapies

• Vaccinations in patients with inflammatory bowel disease

• UK IBD Twin Registry: Concordance and Environmental Risk Factors of Twins with IBD

• Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

• Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis

• Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease

• Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis

• Reshaping of bacterial molecular hydrogen metabolism contributes to the outgrowth of commensal E. coli during gut inflammation

• Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone

• Positive Predictive Value of Diagnostic Codes for Inflammatory Bowel Disease in the Danish National Patient Registry Among Individuals 50+ Years, Using Patient Records as Reference Standard

• Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-a Antagonists in Patients with Inflammatory Bowel Diseases

• Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's disease: A Systematic Review

• The role of telemedicine in the management of inflammatory bowel disease: a systematic review protocol

• The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

• Is Intestinal Diversion an Effective Treatment for Distal Crohn's Disease?

• AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

• Association of atrial fibrillation with outcomes in patients hospitalized with inflammatory bowel disease: an analysis of the National Inpatient Sample

• Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

• New targets in inflammatory bowel disease therapy: 2021

• Epidemiology and clinical course of late onset inflammatory bowel disease

• Post-infection Irritable Bowel Syndrome

• Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic

• Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process

• Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease

• Circulating mature granzyme B+ T cells distinguish Crohn's disease-associated axial spondyloarthritis from axial spondyloarthritis and Crohn's disease

• The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn's Disease

• Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn's Complications-But May Be Preventable

• The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis

• Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions

• Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

• The Impact of Alcohol in Inflammatory Bowel Diseases

• Fecal Diversion for Perianal Crohn Disease in the Era of Biologic Therapies: A Multicenter Study

• International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

• Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change

• Precision Medicine in Inflammatory Bowel Diseases

• Impact of BMGIM Music Therapy on Emotional State in Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial

• Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON ® Gold Testing Useful?

• Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?

• Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk

• Dietary Intakes of Recipients of Faecal Microbiota Transplantation: An Observational Pilot Study

• Steroid use and misuse: a key performance indicator in the management of IBD

• Update on the management of sigmoid diverticulitis

• Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

• The brain-gut axis, inflammatory bowel disease, and bioelectronic medicine

• Influence of systemic manifestations of inflammatory bowel diseases on endothelial function and cardiovascular risk

• Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

• Aging and IBD: A New Challenge for Clinicians and Researchers

• Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions

• Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis

• Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit

• Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease

• Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study

• Training for Minimally Invasive Surgery for IBD: A Current Need

• The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases

• Let Food Be Thy Medicine-Its Role in Crohn's Disease

• The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review

• Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages

• Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System

• Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease

• A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive

• Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease

• Inflammatory bowel disease in patients with congenital chloride diarrhoea

• Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic

• Patient-Evaluated Quality of Care is Related to Better Inflammatory Bowel Disease Outcomes: The IQCARO II Project

• Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

• The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing

• Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?

• Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program

• Characteristics of Opioid Prescriptions to Veterans With Chronic Gastrointestinal Symptoms and Disorders Dually Enrolled in the Department of Veterans Affairs and Medicare Part D

• The Pathogenesis and Clinical Management of Stricturing Crohn Disease

• Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry

• The "Gum-Gut" Axis in Inflammatory Bowel Diseases: A Hypothesis-Driven Review of Associations and Advances

• Newly Diagnosed Patients with Inflammatory Bowel Disease: The Relationship Between Perceived Psychological Support, Health-Related Quality of Life, and Disease Activity

• Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation

• Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease

• Impact of preoperative enteral nutritional support on postoperative outcome in patients with Crohn's disease complicated by malnutrition. Results of a subgroup analysis of the nationwide cohort registry from the GETAID Chirurgie group

• Managing COVID-19 in patients with inflammatory bowel disease: navigating unprecedented challenges

• Validity and Responsiveness of the Patient-Reported Outcomes Measurement Information System in Children with Ulcerative Colitis

• Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review

• A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases

• Access to inflammatory bowel disease speciality care: the primary healthcare physician perspective

• Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study

• The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease

• Trans-ethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals shared but also ethnicity-specific disease associations

• Modeling drug response using network-based personalized treatment prediction (NetPTP) with applications to inflammatory bowel disease

• Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

• Systematic Review and Meta-Analysis of Outcomes after Ileal Pouch-Anal Anastomosis in Primary Sclerosing Cholangitis-Ulcerative Colitis

• Fish Oil for Inflammatory Bowel Disease: Panacea or Placebo?

• Nutrition in the Management of Inflammatory Bowel Diseases

• Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients

• Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life

• Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients

• Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease

• Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

• International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey

• Association Between Chronic Inflammatory Diseases and Stroke-Associated Pneumonia - An Epidemiological Study

• Specialized Emergency Department Assessment and Multidisciplinary Intervention After Discharge Improve Management of Patients With Inflammatory Bowel Diseases

• Is histological healing a feasible endpoint for ulcerative colitis?

• Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare

• The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time

• Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients' behavior

• Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study

• Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases

• Development and Testing of a New Simplified Endoscopic Mucosal Assessment for Crohn

• Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease

• Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism

• Comparative Evaluation of Conventional Stool Testing and Multiplex Molecular Panel in Outpatients With Relapse of Inflammatory Bowel Disease

• Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis

• Alterations in Heart Rate Variability Associated With Irritable Bowel Syndrome or Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases

• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

• Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study

• Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

• Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis

• The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment

• Pulmonary Manifestations of Inflammatory Bowel Disease in Children

• The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study

• Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease

• Inflammatory Bowel Diseases (IBD) (Inflammatory Bowel Diseases and the Microbiome: Searching the Crime Scene for Clues)

• New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?

• Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment

• Comorbid Diagnosis of Eosinophilic Esophagitis and Inflammatory Bowel Disease in the Pediatric Population

• Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review

• Trabecular Bone Score in Children and Adolescents With Inflammatory Bowel Diseases

• Validity and Reliability of the 8-Item Inventory of Dimensions of Emerging Adulthood in a Sample of Inflammatory Bowel Disease Patients

• Association between statin use and inflammatory bowel diseases: Results from a Swedish, nationwide, population-based case-control study

• The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study

• Financial Toxicity in People With Inflammatory Bowel Disease

• Predictors of Ustekinumab Failure in Crohn

• A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review

• Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection

• Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines

• Randomised clinical trial: combined impact and resistance training in adults with stable Crohn

• Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease

• Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group

• Growth and Puberty in Children with Inflammatory Bowel Diseases

• Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy

• Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases

• Prevalence and Effect of Genetic Risk of Thrombo-embolic Disease in Inflammatory Bowel Disease

• The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies

• Identification of Novel Therapeutic Molecular Targets in Inflammatory Bowel Disease by Using Genetic Databases

• Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases

• Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease

• Inflammatory bowel disease and Parkinson

• Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

• Review of inflammatory bowel disease and COVID-19

• Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians

• Fecal Lactoferrin and Other Stool Markers during Normal Pregnancy and in Inflammatory Bowel Diseases: A Prospective Study and Review of the Literature

• The Efficacy of Antihistamines in Preventing Reactions to Infliximab in Patients With Crohn Disease/Ulcerative Colitis: A Review of the Evidence

• Intake of dietary fibre, red and processed meat and risk of late-onset Chronic Inflammatory Diseases: A prospective Danish study on the "diet, cancer and health" cohort

• Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease

• Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease

• Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

• Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn

• Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease

• Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy

• SSAT State-of-the-Art Conference: Advancements in the Microbiome

• Caregiver and Adolescent Patient Perspectives on Comprehensive Care for Inflammatory Bowel Diseases: Building a Family-Centered Care Delivery Model

• Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

• Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease

• Clinical-stage Approaches for Imaging Chronic Inflammation and Fibrosis in Crohn's Disease

• Emerging treatment options for extraintestinal manifestations in IBD

• Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?

• An International Multicentre Comparison of IBD Related Disability and Validation of the IBDDI

• Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management

• Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions

• Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

• Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease

• Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States

• Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study

• The Gut Microbiome and the Triple Environmental Hit Concept of Inflammatory Bowel Disease Pathogenesis

• A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases

• Variation in Provider Connectedness Associates with Outcomes of Inflammatory Bowel Diseases in an Analysis of Data from a National Health System

• Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease

• Frailty is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases

• Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies

• New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies

• Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey

• Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn's Disease

• Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

• Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials

• The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review

• Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States

• Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

• Systematic review on IBD patients with COVID-19: it is time to take stock

• Long-term safety of vedolizumab for inflammatory bowel disease

• Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study

• Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials

• Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

• Patients with More Severe IBD Get Clostridioides difficile Rather than Clostridioides difficile Increasing the Severity of IBD

• Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study

• Prevalence and duration of gastrointestinal symptoms before diagnosis of Inflammatory Bowel Disease and predictors of timely specialist review: a population-based study

• Point-of-care ultrasound in Inflammatory Bowel Disease

• Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists

• High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease

• Corticosteroids in Inflammatory Bowel Disease patients: a practical guide for physicians

• Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease

• Cigarette Smoking, Coffee Consumption, Alcohol Intake, and Risk of Crohn's Disease and Ulcerative Colitis: A Mendelian Randomization Study

• Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications

• From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

• Durable Clinical and Biochemical but Not Endoscopic Remission in Pediatric Crohn's Disease on Specific Carbohydrate Diet Monotherapy

• Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-related Complications in Patients with Ulcerative Colitis

• A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design

• Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study

• Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis

• Gluten-Free Diet in IBD: Time for a Recommendation?

• Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting

• The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis

• The role of vitamin D in inflammatory bowel disease: a guide for clinical practice

• Social Media Use for Inflammatory Bowel Disease in a Rural Appalachian Population

• Ozanimod induction therapy for patients with moderate to severe Crohn

• Colonoids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes

• Stigma and Disclosure in Patients With Inflammatory Bowel Disease

• Dietary patterns, beliefs and behaviours among individuals with inflammatory bowel disease: a cross-sectional study

• Do specific types of sleep disturbances represent risk factors for poorer health-related quality of life in inflammatory bowel disease? A longitudinal cohort study

• Nutrition and inflammatory bowel disease

• Medical Management of Crohn's Disease

• Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases

• Sex-based differences in inflammatory bowel diseases: a review

• Patients With Inflammatory Bowel Diseases Are at Higher Risk for Meningitis

• Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

• Malnutrition and Quality of Life Among Adult Inflammatory Bowel Disease Patients

• Frailty Is Independently Associated With Mortality in 11 001 Patients With Inflammatory Bowel Diseases

• Gaps Exist in the Comprehensive Care of Children With Inflammatory Bowel Diseases

• Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients

• Responsiveness of the Patient-reported Outcomes Measurement Information System (PROMIS) Pediatric Measures to Changes in Disease Status and Quality of Life Among Children and Adolescents With Crohn's Disease

• Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition

• Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients With Inflammatory Bowel Disease

• Systematic Review: Psychosocial Correlates of Pain in Pediatric Inflammatory Bowel Disease

• Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study

• Total Abdominal Colectomies With Proctectomy Are Associated With Higher 30-Day Readmission Rates in Children With Ulcerative Colitis

• VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study

• Corticosteroids, but Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

• Cytokines in Inflammatory Bowel Diseases - Update 2020

• Candida in IBD: Friend or Foe?

• AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients With COVID-19

• Duodenal Bacterial Load as Determined by Quantitative Polymerase Chain Reaction in Asymptomatic Controls, Functional Gastrointestinal Disorders and Inflammatory Bowel Disease

• Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort

• Black and White Patients With Inflammatory Bowel Disease Show Similar Biologic Use Patterns With Medicaid Insurance

• Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature

• Ulcerative Colitis: Recent Advances in the Understanding of Disease Pathogenesis

• Updates in Diagnosis and Management of Inflammatory Bowel Disease

• A Micro-Longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases

• A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities

• 2019 Novel Coronavirus Disease (COVID-19) in Patients With Inflammatory Bowel Diseases

• Personalised Adherence Support for Maintenance Treatment of Inflammatory Bowel Disease: A Tailored Digital Intervention to Change Adherence-related Beliefs and Barriers

• Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Natural History of Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study

• The Gut Microbial Profile of Preclinical Crohn's Disease Is Similar to that of Healthy Controls

• Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease

• Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome

• Efficacy and Safety of Simultaneous Treatment With Two Biologic Medications in Refractory Crohn's Disease

• Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient

• Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series

• Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series

• Efficacy and Safety of Simultaneous Treatment With Two Biologic Medications in Refractory Crohn

• The Gut Microbial Profile of Preclinical Crohn's Disease Is Similar to That of Healthy Controls

• Factors Associated With Inflammatory Bowel Disease Flare During Pregnancy Among Women With Preconception Remission

• Major Acute Cardiovascular Events in Patients With Inflammatory Bowel Disease

• Roles of Healthcare Professionals in the Management of Chronic Gastrointestinal Diseases With a Focus on Primary Care: A Systematic Review

• British Society of Gastroenterology Guidance for Management of Inflammatory Bowel Disease During the COVID-19 Pandemic

• Postoperative Crohn's Disease Management

• Endoscopy in Inflammatory Bowel Diseases During the COVID-19 Pandemic and Post-Pandemic Period

• Gut Microbiota in Chronic Inflammatory Disorders: A Focus on Pediatric Inflammatory Bowel Diseases and Juvenile Idiopathic Arthritis

• Roles of Healthcare Professionals in the Management of Chronic Gastrointestinal Diseases With a Focus on Primary Care: A Systematic Review

• Beyond Crohn Disease: Current Role of Radiologists in Diagnostic Imaging Assessment of Inflammatory Bowel Disease Transitioning From Pediatric to Adult Patients

• AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

• Increasing Rates of Infective Endocarditis in Patients With Inflammatory Bowel Disease

• Lipocalin 2 Links Inflammation and Ankylosis in the Clinical Overlap of Inflammatory Bowel Disease (IBD) and Ankylosing Spondylitis (AS)

• Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy

• Adherence to Azathioprine/6-Mercaptopurine in Children and Adolescents With Inflammatory Bowel Diseases: A Multimethod Study

• A Systematic Review of the Applications of Artificial Intelligence and Machine Learning in Autoimmune Diseases

• Utility of the MARS-5 in Assessing Medication Adherence in IBD

• Clinical Utility of Fecal Calprotectin in Monitoring Disease Activity and Predicting Relapse in Pregnant Patients With Inflammatory Bowel Diseases

• Systematic Review of Development and Content Validity of Patient-Reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

• Sleep Characteristics and Rest-Activity Rhythms Are Associated With Gastrointestinal Symptoms Among Adults With Inflammatory Bowel Disease

• Knowledge and attitudes towards pregnancy in females with Inflammatory BowelDisease - an international, multi-centre study

• Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease

• Switching to a second thiopurine in adult and elderly patients with inflammatorybowel disease: a nationwide study from the ENEIDA registry

• Caesarean Delivery and Risk of Chronic Inflammatory Diseases (Inflammatory BowelDisease, Rheumatoid Arthritis, Coeliac Disease, and Diabetes Mellitus): A Population Based Registry Study of 2,699,479 Births in Denmark During 1973-2016

• Introduction to and Screening Visit Results of the Multicenter Pediatric Crohn

• AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic

• Inflammatory Bowel Disease and Obstructive Pulmonary Disease: A Two-way Association?

• Optimizing Immunization Strategies in Patients with IBD

• COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN

• Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases

• Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

• Sleep Characteristics and Rest-Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease

• Utility of the MARS-5 in Assessing Medication Adherence in IBD

• Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases

• Inflammatory Bowel Disease: A Nationwide Study of Hip Fracture and Mortality Risk after Hip Fracture

• Healthy Lifestyle is Associated with Reduced Mortality in Patients with Inflammatory Bowel Diseases

• Progression of Elderly-Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-based Cohort Studies

• Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?

• Comparison of Disease Phenotypes and Clinical Characteristics Among South Asian and White Patients with Inflammatory Bowel Disease at a Tertiary Referral Center

• Patterns of Primary, Specialty, Urgent Care, and Emergency Department Care in Children with Inflammatory Bowel Diseases

• Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases

• Transition Readiness Not Associated With Measures of Health in Youth With IBD

• Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn’s Disease

• Cytomegalovirus infection is associated with worse outcomes in inflammatory boweldisease hospitalizations nationwide

• Role of cannabis in inflammatory bowel diseases

• Mental Health Costs of Inflammatory Bowel Diseases

• Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey

• Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases

• Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn

• Circulating Leptin Levels as a Potential Biomarker in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

• Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease

• Cardiovascular risk factors are not present in adolescents with inflammatory bowel disease

• The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD

• Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated with Monogenic Variants, Identified by Whole-exome Sequencing in 1000 Children at a Single Center

• Quality of life in inflammatory bowel diseases: it is not all about the bowel

• Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

• Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis

• The role of a plant-based diet in the pathogenesis, etiology and management of the inflammatory bowel diseases

• Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Quality of care standards in inflammatory bowel diseases: a European Crohn

• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn

• Neurological Adverse Effects Associated with anti-TNF Alpha Antibodies in Pediatric Inflammatory Bowel Diseases

• Precision medicine in inflammatory bowel disease: concept, progress and challenges

• The Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease

• Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016)

• Gender Differences in Inflammatory Bowel Disease

• Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

• A three-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring program of infliximab treatments in inflammatory bowel disease

• Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block

• Children and young people with inflammatory bowel disease attend less school than their healthy peers

• Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn

• Integrated Psychological Care Reduces Healthcare Costs at a Hospital-Based Inflammatory Bowel Disease Service

• Prevalence and Risk Factors of Substance Use Disorder in Inflammatory BowelDisease

• Knowledge of disease and self-management of adolescents with inflammatory bowel diseases

• Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach

• Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study

• The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

• Host engulfment pathway controls inflammation in Inflammatory Bowel Disease

• Sleep and Fatigue in IBD: an Unrecognized but Important Extra-intestinal Manifestation

• Exposure to Intravenous Opioids is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases

• Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study

• Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease.

• Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease

• Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease

• Use of Synbiotics for Ulcerative Colitis Treatment

• Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis

• Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

• Incidence Rates for Surgery in Crohn

• Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies

• Poor Sleep Quality in Crohn

• Diet Therapy for Inflammatory Bowel Diseases: A Call to the Dining Table

• Diet in treatment of Inflammatory Bowel Diseases

• Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings?

• ECCO Guidelines on Therapeutics in Crohn

• Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Diseases Caused by TTC7A Deficiency

• Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?

• Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn

• The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease

• IBD in the Elderly: Management Challenges and Therapeutic Considerations

• Upper Gastrointestinal Disease Influences the Occurrence of Inflammatory Bowel Disease

• Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications

• Potential of Electrical Neuromodulation for Inflammatory Bowel Disease

• Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-a Intervention in Pediatric Crohn

• Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn

• Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study

• Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence

• Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old or Obstetric

• Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and InflammatoryBowel Disease: A Review from Clinical Trials and Regulatory Documents

• Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse

• Postoperative Considerations in Inflammatory Bowel Disease

• Elective Abdominal Surgery for Inflammatory Bowel Disease

• Pediatric Inflammatory Bowel Disease: Special Considerations

• Ileal Pouch Complications

• Genetic and Environmental Considerations for Inflammatory Bowel Disease

• Inflammatory bowel diseases: interrelationships between dietary vitamin D, exposure to UV radiation and the fecal microbiome

• Association between inflammatory bowel disease and chronic obstructive pulmonary disease: a systematic review and meta-analysis

• Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences

• Inflammatory Bowel Disease Presentation and Diagnosis

• Endoscopy in Inflammatory Bowel Disease

• Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease

• Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease

• Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery

• Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease

• Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease

• Bariatric Surgery and Its Complications in Inflammatory Bowel Disease Patients

• Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis

• A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients

• Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease

• Characterizing Clinical Features and Creating a Gene Expression Profile Associated With Pain Burden in Children With Inflammatory Bowel Disease

• Histopathological Mimics of Inflammatory Bowel Disease

• Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study

• Inflammatory Bowel Diseases and Parkinson

• Cannabis for the Treatment of Crohn

• Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease

• Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States

• Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis

• Nanotechnology in the Treatment of Inflammatory Bowel Disease

• The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease

• Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring

• Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

• Ursodeoxycholic acid: A promising therapeutic target for inflammatory bowel diseases?

• Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts

• Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

• Outcomes of inflammatory bowel disease surgery in obese versus non-obese patients: a meta-analysis

• The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down

• Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn

• Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007-2016

• The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory BowelDisease

• Health Care Cost for Children Newly Diagnosed With Inflammatory Bowel Disease

• Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis

• Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn

• Is ulcerative colitis a disease of a dysfunctional microbiota?

• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn

• Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases

• Dietary strategies and food practices of pediatric patients, and their parents, living with inflammatory bowel disease: a qualitative interview study

• Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases

• A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease

• Rate of, Risk Factors for, and Interventions to Reduce Hospital Readmission in Patients with Inflammatory Bowel Diseases

• Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

• Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases

• Comparison of Time to Pregnancy in Women With and Without Inflammatory Bowel Diseases

• Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn

• Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn

• Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease

• Novel Microbial-Based Immunotherapy Approach for Crohn

• Lower Gastrointestinal Conditions: Inflammatory Bowel Disease

• Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT

• Is ulcerative colitis a disease of a dysfunctional microbiota?

• Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy

• Inflammatory bowel disease patient profiles are related to specific information needs: A nationwide survey

• Variation of Gut Mucosal Microbiome with ASCA Status in Pediatric Crohn

• Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases

• Thoracic Manifestations of Ankylosing Spondylitis, Inflammatory Bowel Disease, and Relapsing Polychondritis

• Achieving mucosal healing in inflammatory bowel diseases: which drug concentrations need to be targeted?

• Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn

• Recent Advances in Gut Microbiota Mediated Therapeutic Targets in Inflammatory Bowel Diseases: Emerging Modalities for Future Pharmacological Implications

• Lower Gastrointestinal Conditions: Inflammatory Bowel Disease

• Portomesenteric Venous Thrombosis in Patients Undergoing Surgery for Medically Refractory Ulcerative Colitis

• Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations

• Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies

• Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway?

• Genome-wide copy number variant data for inflammatory bowel disease in a caucasian population

• Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With InflammatoryBowel Disease: A Canadian Population-Based Study

• Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory BowelDisease

• Novel Microbial-Based Immunotherapy Approach for Crohn

• Diagnostic Approach to Monogenic Inflammatory Bowel Disease in Clinical Practice: A Ten-Year Multicentric Experience

• Bone Health in Patients With Inflammatory Bowel Diseases

• Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases

• A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD

• Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

• Viewpoint: Inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations

• Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence

• Micronutrient Deficiencies in Children With Inflammatory Bowel Diseases

• Pharmacology, efficacy and safety of JAK inhibitors in Crohn

• Opportunistic Infections Are More Prevalent in Crohn

• Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm

• Evolving Epidemiology of IBD

• Ulcerative Colitis and Crohn

• Initial Development and Validation of a Transition Readiness Scale for Adolescents with Inflammatory Bowel Disease

• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn

• Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases

• Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases

• Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine

• The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases

• Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials

• Patients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications

• Patients Perception of Risks and Benefits of Biologic Therapy

• Mortality After First Hospital Admission for Inflammatory Bowel Disease: A Nationwide Registry Linkage Study

• Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

• Development of collagenous colitis in inflammatory bowel disease: two case reports and a review of the literature

• Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis

• Refractory Complex Crohn

• Risk Factors for Venous Thromboembolism in Children and Young Adults With InflammatoryBowel Disease

• Inflammatory bowel disease masquerading as traveller

• Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn

• Comorbidities in inflammatory bowel disease: a call for action

• Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science

• Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows

• Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy

• The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn

• CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease

• Bariatric Surgery Is a Safe and Effective Option for Patients with Inflammatory Bowel Diseases: A Case Series and Systematic Review of the Literature

• Challenges in IBD Research: Pragmatic Clinical Research

• Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

• Challenges in IBD Research: Environmental Triggers

• Challenges in IBD Research: Precision Medicine

• Challenges in IBD Research: Novel Technologies

• Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT

• The vitamin D positive feedback hypothesis of inflammatory bowel diseases

• Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?

• Prognosticating the Course of Inflammatory Bowel Disease

• Comparative Incidence of Inflammatory Bowel Disease in Different Age Groups in the United States

• Recommendations for Successful Transition of Adolescents With Inflammatory Bowel Diseasesto Adult Care

• A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn

• Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals

• Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases

• Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial

• US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease

• Assessment of the procoagulant potential and associated risk factors in pregnant patients with inflammatory bowel diseases

• Pediatric inflammatory bowel disease: continuous lessons for adult inflammatory bowel disease

• Histologic Remission in Ulcerative Colitis: Are We There Yet?

• Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses

• Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease

• Long-term clinical effectiveness of ustekinumab in patients with Crohn

• Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis

• Detection and management of early stage inflammatory bowel disease: an update for clinicians

• Should We Divide Crohn's Disease Into Ileum-dominant and Isolated Colonic Diseases?

• The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

• Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial

• Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol

• Clock Gene Disruption is an Initial Manifestation of Inflammatory Bowel Disease

• Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis

• Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

• Emerging roles of bile acids in mucosal immunity and inflammation

• Impact of inflammatory bowel diseases on working life: A French nationwide survey

• Informed Consent in IBD Trials: Where We Are and Where We Need to Go

• Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort

• Increased Healthcare Utilization by Patients With Inflammatory Bowel DiseaseCovered by Medicaid at a Tertiary Care Center

• Risk of Infection and Types of Infection Among Elderly Patients With InflammatoryBowel Disease: A Retrospective Database Analysis

• Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary

• Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies

• Hepatic Complications of Inflammatory Bowel Disease

• Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory BowelDisease

• Assessment of Crohn

• The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application

• The Inflammatory Bowel Disease Medical Home: From Patients to Populations

• Food-related quality of life in patientswith inflammatory bowel disease and irritable bowel syndrome

• Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study

• Infliximab in inflammatory bowel disease

• Updates in the management of inflammatory bowel disease during pregnancy

• Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

• The Role of Vitamin D in Elderly Inflammatory Bowel Disease Patients

• The Incidence and Prevalence of Inflammatory Bowel Disease in the Jewish and Arab Populations of Israel

• Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small BowelCrohn

• Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know

• Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases

• Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

• Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease

• The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease

• Sense of coherence in people with and without inflammatory bowel diseases - is there a difference?

• A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease

• Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory BowelDisease in Children and Adolescents

• Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention?

• Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence

• Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases

• Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory BowelDisease Patients

• Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

• Particularities of IBD trials in children

• Interferon-gamma depresses human intestinal smooth muscle cell contractility: Relevance to inflammatory gut motility disturbances

• A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping

• Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity

• Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations

• Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews

• Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn

• Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease

• Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients

• Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases

• Events Within the First Year of Life, but not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases

• Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

• Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process

• Comparative safety and effectiveness of tumor necrosis factor a antagonists and vedolizumab in elderly IBD patients: a multicentre study

• Dietary interventions for induction and maintenance of remission in inflammatory bowel disease

• Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region

• Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn

• A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory BowelDisease

• Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease

• Overlapping irritable bowel syndrome and inflammatory bowel disease

• Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases

• Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn

• Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease

• Probiotics in the Treatment of Inflammatory Bowel Disease

• The Incidence and Definition of Crohn

• Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression

• Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with InflammatoryBowel Disease

• Westernized Diet is the Most Ubiquitous Environmental Factor in Inflammatory Bowel Disease

• Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis

• The Juncture between Clostridium difficile infection and Inflammatory Bowel Diseases

• More Than a Tumor Marker?A Potential Role for Alpha-Feto Protein in Inflammatory BowelDisease

• Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study

• Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3

• Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?

• The connection of circadian rhythm to inflammatory bowel disease

• Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis

• Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease

• Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis

• Managing Risks with Biologics

• Mechanisms of Disease: Inflammatory Bowel Diseases

• Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases

• Scope of Burnout Among Young Gastroenterologists and Practical Solutions from Gastroenterology and Other Disciplines

• Factors affecting vitamin D deficiency in active inflammatory bowel diseases

• High Patient Activation Is Associated With Remission in Patients With Inflammatory BowelDisease

• Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis

• The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

• Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel Disease

• American Gastroenterological Association Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis

• Choosing an appropriate probiotic product for your patient: An evidence-based practical guide

• Use of Probiotics to Prevent Celiac Disease and IBD in Pediatrics

• A Randomized Crossover Trial of Conventional vs Virtual Chromoendoscopy for Colitis Surveillance: Dysplasia Detection, Feasibility, and Patient Acceptability (CONVINCE)

• Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies

• Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease

• Social Stress Affects Colonic Inflammation, the Gut Microbiome, and Short Chain Fatty Acid Levels and Receptors

• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?

• Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease

• Inflammatory Bowel Disease and the Risk of Prostate Cancer

• Risk of Myocardial Infarction in Inflammatory Bowel Disease: A Population-based National Study

• IBDoc Canadian User Performance Evaluation

• Acupuncture in Inflammatory Bowel Disease

• Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study

• Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

• Trends and Attributable Costs of Anorectal Involvement in Pediatric Crohn's Disease

• Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals

• Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease

• The Prevalence and Clinical Associations of Subclinical Sacroiliitis in Inflammatory BowelDisease

• Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case-Control Study

• A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD

• Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases

• Inflammatory Bowel Diseases and School Absenteeism

• Clinical Application and Potential of Fecal Microbiota Transplantation

• Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go?

• Epigenetics, DNA Organization, and Inflammatory Bowel Disease

• A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease

• Healing of Apical Periodontitis in Patients with Inflammatory Bowel Diseases and under Anti-tumor Necrosis Factor Alpha Therapy

• Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

• Probiotics for gastrointestinal and liver diseases: an updated review of the published literature

• PCR Based Fecal Pathogen Panel Testing Should Be Interpreted with Caution at Diagnosis of Pediatric Inflammatory Bowel Diseases

• Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases

• Emerging Therapies for Inflammatory Bowel Disease

• Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study

• Clear liquid diet before bowel preparation predicts successful chromoendoscopy in patients with inflammatory bowel disease

• Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort

• The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn's and Colitis Foundation

• Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology

• Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases

• Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach

• Emergent Behavior of IBD-Associated Escherichia coli During Disease

• Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile

• The association of Inflammatory Bowel diseases with autoimmune disorders: a population-based report from the epi-IIRN

• Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity

• Thrombotic and Infectious Risks of Parenteral Nutrition in Hospitalized Pediatric InflammatoryBowel Disease

• A Practical Guide to the Safety and Monitoring of New IBD Therapies

• Very early onset IBD: novel genetic aetiologies

• Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience

• Web-based learning in inflammatory bowel diseases: General truths and current specifics

• Update on Vaccinating the Patient With Inflammatory Bowel Disease

• Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort

• Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

• A Systematic Review of Self-Management Interventions for Children and Adolescents With Inflammatory Bowel Disease

• The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity

• Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease?

• Overall and Cause-Specific Mortality of Inflammatory Bowel Disease in Olmsted County, Minnesota, From 1970 Through 2016

• Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases

• Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

• Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease

• Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease

• Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection

• Reporting Colonic Biopsies in Patients With Inflammatory Bowel Disease; a Practical Approach

• The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for InflammatoryBowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios

• Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections After Arthroplasty

• Index Severity Score and Early Readmission Predicts Increased Mortality in Ulcerative Colitis Patients

• Use of Precision Medicine in Clinical Trials in Inflammatory Bowel Disease

• Preventive Health Care Among Postpartum Women With Inflammatory Bowel Disease: Results From the PIANO Registry

• Co-occurrence of Asthma and the Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

• Fatigue and its associated factors in microscopic colitis

• Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's disease

• Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life

• Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease

• Social Media Use and Preferences in Patients With Inflammatory Bowel Disease

• Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives

• Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatorybowel disease

• A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population

• Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise

• The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

• A Systematic Review of Micronutrient Deficiencies in Pediatric Inflammatory Bowel Disease

• Early onset inflammatory bowel disease - What the radiologist needs to know

• Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise

• The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

• A Systematic Review of Micronutrient Deficiencies in Pediatric Inflammatory Bowel Disease

• Early onset inflammatory bowel disease - What the radiologist needs to know

• Interdisciplinary Updates in Crohn's Disease Reporting Nomenclature, and Cross-Sectional Disease Monitoring

• Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases

• A Comprehensive Approach to Pouch Disorders

• Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition

• Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn's Disease

• Small Bowel Lesions Mimicking Crohn's Disease

• Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study

• A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study

• Evolution of Clinical Trials in Inflammatory Bowel Diseases

• Sex-based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-based Studies from Western Countries

• Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome

• MRI of the bowel - beyond inflammatory bowel disease

• Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

• Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases

• The evidence for fungus in Crohn's disease pathogenesis

• Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease

• Obesity is Independently Associated with Higher Annual Burden and Costs of Hospitalization in Patients with Inflammatory Bowel Diseases

• Novel Imaging Approaches in Inflammatory Bowel Diseases

• Defining Failure of Medical Therapy for Inflammatory Bowel Disease

• Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease

• Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails

• Robust Microbial Markers for Non-Invasive Inflammatory Bowel Disease Identification

• Limited Health Literacy Is Associated With Worse Patient-Reported Outcomes in Inflammatory Bowel Disease

• Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review

• Predicting Risk of Postoperative Disease Recurrence in Crohn's Disease: Patients With Indolent Crohn's Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery

• Oligonucleotide-Based Therapies for Inflammatory Bowel Disease

• Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis

• High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment

• The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies

• Is There a Role for Thiopurines in IBD?

• Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study

• Mimics of Inflammatory Bowel Disease

• Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis

• Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndromeand inflammatory bowel disease

• Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results

• The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD

• A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study

• Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

• Inflammatory bowel disease: new therapies from antisense oligonucleotides

• Smoking and Inflammatory Bowel Disease: A Comparison of China, India, and the USA

• The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease

• The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease

• Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials

• Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles

• Rapid response to vedolizumab therapy in biologic-na?ve patients with inflammatory bowel diseases

• Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease

• Academic Stress May Contribute to the Onset of Pediatric Inflammatory Bowel Diseases

• Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development

• Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

• Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease

• Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation

• Multicenter Evaluation of Emergency Department Treatment for Children and Adolescents With Crohn's Disease According to Race/Ethnicity and Insurance Payor Status

• Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

• Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 Year

• Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials

• Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease

• Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease

• Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study

• Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease

• Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention

• Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases

• Variation in Interleukin 6 Receptor Gene Associates with Risk of Crohn's Diseaseand Ulcerative Colitis

• Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases

• Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease

• Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement

• Current Landscape of Telemedicine Practice in Inflammatory Bowel Disease

• Management of Pouchitis and Other Common Complications of the Pouch

• Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease

• Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?

• Perceived Illness Stigma, Thwarted Belongingness, and Depressive Symptoms in Youth With Inflammatory Bowel Disease (IBD)

• Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies

• Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis

• Low Incidence of Dysplasia and Colorectal Cancer Observed among Inflammatory Bowel Disease Patients with Prolonged Colonic Diversion

• Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases

• Restless legs syndrome is a relevant comorbidity in patients with inflammatorybowel disease

• Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases

• Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Fecal Microbiota Transplantation in Inflammatory Bowel Disease- a Primer for the Internists

• Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex Life

• Genetic variants and pathways implicated in a pediatric inflammatory bowel disease cohort

• Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease

• Hispanic Americans and Non-Hispanic White Americans Have a Similar Inflammatory Bowel Disease Phenotype: A Systematic Review with Meta-Analysis

• CT utilization abruptly increases at age 18 among patients with inflammatory bowel diseases in the hospital

• Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I

• Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel diseaseamong patients with type 2 diabetes: population based cohort study

• Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis

• Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people

• The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis

• Classification of pediatric functional gastrointestinal disorders related to abdominal pain using Rome III vs. Rome IV criterions

• New treatment options for inflammatory bowel diseases

• Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients

• Dysplasia in inflammatory bowel disease

• Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients

• Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies

• A randomised controlled trial, cost-effectiveness and process evaluation of the implementation of self-management for chronic gastrointestinal disorders in primary care, and linked projects on identification and risk assessment.

• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis

• Stopping Biologics in IBD-What Is the Evidence?

• Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review

• Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis

• Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

• Mechanical Bowel Preparation (MBP) Prior to Elective Colorectal Resections in Crohn's Disease Patients.

• The Management of Intestinal Penetrating Crohn's Disease

• An Update on Surveillance in Ulcerative Colitis

• Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease

• Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory BowelDisease

• Methotrexate Reduces DNA Integrity in Sperm From Men with InflammatoryBowel Disease

• Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

• Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity

• Segmental Resection versus Total Proctocolectomy for Crohn's Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia?

• Mendelian Disease Associations Reveal Novel Insights into Inflammatory BowelDisease

• Duodenal Crohn's Disease

• Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience

• Clinical and Genomic Correlates of Neutrophil Reactive Oxygen Species Production in Pediatric Patients with Crohn's Disease

• The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease

• Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease

• Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries

• Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population

• Filgotinib for the treatment of Crohn's disease

• Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study

• Stool PCR for Gastrointestinal Pathogens in Patients With and Without Immune-Mediated Intestinal Diseases

• Associations between physical activity, resilience, and quality of life in people with inflammatory bowel disease

• Novel Therapies and Treatment Strategies for Patients with Inflammatory BowelDisease

• The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases

• Best Practice Update: Incorporating Psycho-gastroenterology into Management of Digestive Disorders

• Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases

• Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease

• Anti-Tnf Therapeutic Drug Monitoring in Post-Operative Crohn's Disease

• Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

• Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's DiseaseTreated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients

• Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography

• Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease

• A Mobile Infliximab Dosing Calculator for Therapy Optimization in InflammatoryBowel Disease

• Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014

• The Addition of an Immunosuppressant After Loss of Response to Anti-TNF? Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

• The Influence of Hormonal Fluctuation on Inflammatory Bowel Disease Symptom Severity-A Cross-Sectional Cohort Study

• Characteristics and comorbidities of inpatients without celiac disease on a gluten-free diet

• Long ncRNA Landscape in the Ileum of Treatment-Naive Early-Onset Crohn Disease

• Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity

• Systematic review: psychosocial factors associated with pain in inflammatorybowel disease

• Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease

• The Natural History of IBD: Lessons Learned

• Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy

• Characteristics and comorbidities of inpatients without celiac disease on a gluten-free diet

• Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-?-Directed Therapy for InflammatoryBowel Disease

• Rescue Diverting Loop Ileostomy: An Alternative to Emergent Colectomy in the Setting of Severe Acute Refractory IBD-Colitis

• Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease

• Exercise in patients with inflammatory bowel diseases: current perspectives

• Dynamics of metatranscription in the inflammatory bowel disease gut microbiome

• Predicting and explaining inflammation in Crohn's disease patients using predictive analytics methods and electronic medical record data

• Inflammatory Bowel Disease Is Not a Contraindication for Bariatric Surgery

• Association of Vedolizumab Level, Anti-drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

• The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease

• Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease. A meta-analysis

• Genetic profile of patients with early onset inflammatory bowel disease

• Serologic, Genetic, and Clinical Associations with Increased Healthcare Resource Utilization in Inflammatory Bowel Disease

• Genetic profile of patients with early onset inflammatory bowel disease

• Factors Associated With Length of Stay in Veterans With Inflammatory BowelDisease Hospitalized for an Acute Flare

• Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice

• The Informational Needs and Preferences of Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study

• Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease

• IBD Serology and Disease Outcomes in African Americans With Crohn's Disease

• Suicidal Behavior Among Hospitalized Adults With Inflammatory Bowel Disease: A United States Nationwide Analysis

• A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory BowelDisease

• YouTube as a source of information for patients considering surgery for ulcerative colitis

• Maternal history of recurrent pregnancy loss is associated with increased risk for long-term pediatric gastrointestinal morbidity in the offspring

• Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

• Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-? inhibitors or nonbiologic agents: a cohort study

• Sleep and Circadian Hygiene and Inflammatory Bowel Disease

• Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease

• Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future Directions

• Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study

• Mindfulness-Based Interventions in Inflammatory Bowel Disease

• Difference in clinical course, genetics, and the microbiome between familial and sporadic inflammatory bowel diseases

• Preventing disability in inflammatory bowel disease

• Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs

• Minority Pediatric Patients with Inflammatory Bowel Disease Demonstrate an Increased Length of Stay

• Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease

• Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit

• Adherent-invasive Escherichia coli in inflammatory bowel disease

• Medication adherence in inflammatory bowel disease

• Increasing Prescription of Opiates and Mortality in Patients with Inflammatory Bowel Diseases in England

• What Is the Risk of Anastomotic Leak After Repeat Intestinal Resection in Patients With Crohn's Disease?

• A Pilot Study of the Prevalence of Anal Human Papillomavirus and Dysplasia in a Cohort of Patients With IBD

• Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France

• Systematic review: advice lines for patients with inflammatory bowel disease

• An Update on Inflammatory Bowel Disease

• Long-term outcomes of pediatric inflammatory bowel disease

• Medical management of pediatric inflammatory bowel disease

• Reliability and validity of the Beliefs About Medication Scale in pediatric inflammatory bowel disease

• Population Health Management for Inflammatory Bowel Disease

• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

• Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study

• Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis

• Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease

• Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

• Crohn's Disease of the Pouch: A True Diagnosis or an Oversubscribed Diagnosis of Exclusion?

• DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate DiseaseSubtypes and Associate With Outcome

• Pharmacotranscriptomic biomarkers in glucocorticoid treatment of pediatric inflammatory bowel disease

• Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-based Cohort Study

• Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease

• Oral manifestations of inflammatory bowel disease

• European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease

• Targeted Gene Panel Sequencing for Early-onset Inflammatory Bowel Diseaseand Chronic Diarrhea

• E-health in inflammatory bowel diseases: More challenges than opportunities?

• Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease

• Can We Predict the Efficacy of Anti-TNF-? Agents?

• Obese Patients Undergoing Ileal Pouch-Anal Anastomosis: Short- and Long-term Surgical Outcomes

• Intrinsic neural network dysfunction in quiescent Crohn's Disease

• Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis

• Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort

• Inflammatory diseases and bone fragility

• Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry

• Inflammatory Diseases and Growth: Effects on the GH-IGF Axis and on Growth Plate

• Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis

• Increased incidence of psychiatric disorders in immune-mediated inflammatory disease

• Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases

• Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches

• Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study

• Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

• Experience of menopause in women with inflammatory bowel disease: pilot study

• Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease

• Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new

• Assessing the Transition Intervention Needs of Young Adults With Inflammatory Bowel Diseases

• Eosinophilia and Ulcerative Colitis Associated with Eosinophilic Myocarditis

• Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease

• Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease

• Nutritional Therapy in Very Early-Onset Inflammatory Bowel Disease: A Case Report

• Chronological age when healthcare transition skills are mastered in adolescents/young adults with inflammatory bowel disease.

• Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-? medications among patients with inflammatory bowel diseases

• The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease

• Issues in Nutrition: Dietary Considerations in Select Chronic Conditions

• Clostridium difficile Infection and Risk of Colectomy in Patients with Inflammatory Bowel Disease: A Bias-adjusted Meta-analysis

• Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins

• Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database

• Effects of a Cognitive Behavioral Therapy Intervention Trial to Improve Disease Outcomes in Children with Inflammatory Bowel Disease

• Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort: The IBD Self-efficacy Scale

• Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases

• Hormonal Contraception Use is Common Among Patients with Inflammatory Bowel Diseases and an Elevated Risk of Deep Vein Thrombosis

• Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease

• Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases

• Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases

• Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use

• Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment

• Using Computerized Physician Order Entry to Ensure Appropriate Vaccination of Patients with Inflammatory Bowel Disease

• Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease

• Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis

• Intestinal inflammation and the diet: Is food friend or foe?

• Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry

• Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease

• Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease

• Inpatient Costs for Patients with Inflammatory Bowel Disease and Acute Pancreatitis

• Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease

• Relationship of Bowel MR Imaging to Health-related Quality of Life Measures in Newly Diagnosed Pediatric Small Bowel Crohn Disease

• Upper Gastrointestinal Tract in Inflammatory Bowel Disease

• Does Crohn's Disease with Concomitant Orofacial Granulomatosis Represent a Distinctive Disease Subtype?

• Transition of Inflammatory Bowel Disease Care: Assessment of Transition Readiness Factors and Disease Outcomes in a Young Adult Population

• Association Between Circulating Levels of C-reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease

• Feeling Fine: Anxiety and Depressive Symptoms in Youth with Established IBD

• Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab

• Current Transition Practices in Pediatric IBD: Findings from a National Survey of Pediatric Providers

• Preclinical and Undiagnosed Crohn's Disease: The Submerged Iceberg

• Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper from ESPGHAN, ECCO, PIBDnet and the Canadian Children IBD Network

• A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

• Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

• Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis

• A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection

• Food-related Quality of Life in Inflammatory Bowel Disease: Development and Validation of a Questionnaire

• Increased Risk of Oral Cancer in Patients With Inflammatory Bowel Diseases

• Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

• Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases

• Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases - a prospective study on incidence and severity

• Vedolizumab: an ?4?7 integrin antagonist for ulcerative colitis and Crohn's disease

• Postoperative Complications in Pediatric Inflammatory Bowel Disease: A Population-based Study

• Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease

• Cognitive Function of Patients with Crohn's Disease is Associated with Intestinal Disease Activity

• Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis

• Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States

• Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis

• Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings

• Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease

• Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

• Perioperative Parenteral Nutrition in Adults With Inflammatory Bowel Disease: A Review of the Literature

• Childhood Maltreatment Is Associated with Ulcerative Colitis but Not Crohn's Disease: Findings from a Population-based Study

• The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease

• Maternal High-fat Diet Accelerates Development of Crohn's Disease-like Ileitis in TNF?ARE/WT Offspring

• Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

• Endoscopic Therapy in Crohn's Disease: Principle, Preparation, and Technique

• Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case-control study

• Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection

• The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention

• Video Capsule Endoscopy of the Small Bowel for Monitoring of Crohn's Disease

• Robust Association Between Inflammatory Bowel Disease and Generalized Anxiety Disorder: Findings from a Nationally Representative Canadian Study

• A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel Disease

• U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis

• Serology of Patients with Ulcerative Colitis After Pouch Surgery Is More Comparable with that of Patients with Crohn's Disease

• Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease

• Cogan's Syndrome in Patients With Inflammatory Bowel Disease - a Case Series

• Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease

• Autonomic Dysfunction Correlates with Clinical and Inflammatory Activity in Patients with Crohn's Disease

• Low Risk of Unemployment, Sick Leave, and Work Disability Among Patients with Inflammatory Bowel Disease: A 7-year Follow-up Study of a Danish Inception Cohort

• Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry

• Biomarkers of Inflammation in Inflammatory Bowel Disease

• Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis

• Targeting Medication Non-Adherence Behavior in Selected Autoimmune Diseases: A Systematic Approach to Digital Health Program Development

• Higher Rates of Dose Optimization for Infliximab Responders in Ulcerative Colitis than in Crohn's disease

• Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities

• Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis

• Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

• High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease

• Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

• Older Age and Steroid Use Are Associated with Increasing Polypharmacy and Potential Medication Interactions Among Patients with Inflammatory Bowel Disease

• Advances in the Endoscopic Assessment of Inflammatory Bowel Diseases: Cooperation between Endoscopic and Pathologic Evaluations

• When it is not inflammatory bowel disease: differential diagnosis

• Use of Intravenous Immunoglobulin for Patients with Inflammatory Bowel Disease with Contraindications or Who Are Unresponsive to Conventional Treatments

• Analysis of exhaled breath volatile organic compounds in inflammatory bowel disease: a pilot study

• Transition of gastroenterological patients from paediatric to adult care: A position statement by the Italian Societies of Gastroenterology

• How to represent the decision process in a medication plan: the case of the swiss cohort of inflammatory bowel diseases

• Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis

• A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases

• Impact of Quality Improvement Educational Interventions on Documented Adherence to Quality Measures for Adults with Crohn's Disease

• Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study

• A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases

• Minimally invasive surgery for inflammatory bowel disease

• Current therapy of pediatric Crohn's disease

• Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease

• Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations

• Briakinumab for treatment of Crohn's disease: results of a randomized trial

• Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease

• Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease

• Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: a 10-year tertiary referral center experience

• Infliximab Does Not Worsen Outcomes During Flare-ups Associated with CMV Infection in Patients with UC

• Concerns, Barriers, and Recommendations to Improve Transition from Pediatric to Adult IBD Care: Perspectives of Patients, Parents, and Health Professionals

• Tools for primary care management of inflammatory bowel disease: Do they exist?

• Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care

• Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-analysis

• Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases

• Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review

• Experiences of healing therapy in patients with irritable bowel syndrome and inflammatory bowel disease

• Disease-related pregnancy concerns and reproductive planning in women with inflammatory bowel diseases

• Inflammatory Bowel Disease and the Elderly: A Review

• Nutritional therapy in inflammatory bowel disease

• Thrombosis in inflammatory bowel diseases: what's the link?

• Golimumab: clinical update on its use for ulcerative colitis

• Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease

• Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases

• Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease

• Emergency Department Visits Related to Inflammatory Bowel Disease: Results From Nationwide Emergency Department Sample

• The clinical implications of thalidomide in inflammatory bowel diseases

• Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

• Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis

• Older Age and Steroid Use Are Associated with Increasing Polypharmacy and Potential Medication Interactions Among Patients with Inflammatory Bowel Disease

• Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis

• Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

• High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease

• Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

• Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities

• A Review of the Impact of Biologics on Surgical Complications in Crohn's Disease

• Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?

• In Vitro Fertilization in Women with Inflammatory Bowel Disease is as Successful as inWomen from the General Infertility Population

• TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial

• Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis

• STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?

• What Role Does Mycobacterium avium subsp. paratuberculosis Play in Crohn's Disease?

• Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

• Comparison of Frequency of Inflammatory Bowel Disease and Noninfectious Gastroenteritis Among Statin Users Versus Nonusers

• Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease

• IBD and the Gut Microbiota-from Bench to Personalized Medicine

• Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases

• Variation in incidence of pediatric Crohn's disease in relation to latitude and ambient ultraviolet radiation: a systematic review and analysis

• High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-predominant Irritable Bowel Syndrome Based on Rome III Criteria

• Management of Intra-abdominal Abscesses in Children With Crohn's Disease: A 12-year, Retrospective Single-center Review

• Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease

• Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011

• Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey

• Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease

• Real-life outcome of anti-tumor necrosis factor ? in the ambulatory treatment of ulcerative colitis

• Transition Readiness Skills Acquisition in Adolescents and Young Adults with Inflammatory Bowel Disease: Findings from Integrating Assessment into Clinical Practice

• Endoscopic Evaluation of Surgically Altered Bowel in Patients with Inflammatory Bowel Diseases

• Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study

• Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis

• STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?

• What Role Does Mycobacterium avium subsp. paratuberculosis Play in Crohn's Disease?

• Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

• Comparison of Frequency of Inflammatory Bowel Disease and Noninfectious Gastroenteritis Among Statin Users Versus Nonusers

• Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease

• IBD and the Gut Microbiota-from Bench to Personalized Medicine

• Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases

• Variation in incidence of pediatric Crohn's disease in relation to latitude and ambient ultraviolet radiation: a systematic review and analysis

• Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNF? Therapy

• Snapshot of an integrated psychosocial gastroenterology service

• Laboratory markers in ulcerative colitis: Current insights and future advances

• Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease

• Bridging the Gap Between Host Immune Response and Intestinal Dysbiosis in Inflammatory Bowel Disease: Does IgA Mark the Spot?

• Pharmacokinetics and Exposure-Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn's Disease: Results from a Randomized, Multicenter, Phase-3 Study

• Exercise Decreases Risk of Future Active Disease in Patients with Inflammatory Bowel Disease in Remission

• A Study Evaluating the Bidirectional Relationship Between Inflammatory Bowel Disease and Self-reported Non-celiac Gluten Sensitivity

• Management of arthropathy in inflammatory bowel diseases

• Evaluation of histologic features with potential prognostic value in ulcerative colitis

• Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

• A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS

• High amount of dietary fiber not harmful but favorable for crohn disease

• Pneumococcal Vaccination Rates in VHA Patients With Inflammatory Bowel Disease

• Serum C-reactive Protein and CRP Genotype in Pediatric Inflammatory Bowel Disease: Influence on Phenotype, Natural History, and Response to Therapy

• Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

• Objective Structured Clinical Examination as a Novel Tool in Inflammatory Bowel Disease Fellowship Education